{"id":"NCT02170727","sponsor":"Bristol-Myers Squibb","briefTitle":"A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1","officialTitle":"A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06-26","primaryCompletion":"2015-06-12","completion":"2015-09-09","firstPosted":"2014-06-23","resultsPosted":"2019-08-16","lastUpdate":"2020-10-29"},"enrollment":199,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus"],"interventions":[{"type":"DRUG","name":"DCV/ASV/BMS-791325","otherNames":[]}],"arms":[{"label":"Arm 1 : DCV/ASV/BMS-791325","type":"EXPERIMENTAL"}],"summary":"To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 (SVR12) in the Naive Cohort","timeFrame":"Post treatment Week 12","effectByArm":[{"arm":"Treatment-Naive: DCV/ASV/BMS-791325","deltaMin":98.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":20,"countries":["Russia","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx","http://bms.com/studyconnect/Pages/home.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":138},"commonTop":["HEADACHE","UPPER RESPIRATORY TRACT INFECTION","ALANINE AMINOTRANSFERASE INCREASED","DIARRHOEA","MYALGIA"]}}